033270 — Korea United Pharm Share Price
0.000.00%
Last trade - 00:00- KR₩289bn
- KR₩173bn
- KR₩289bn
- 82
- 68
- 52
- 79
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 5.26 | ||
| PEG Ratio (f) | 0.72 | ||
| EPS Growth (f) | 7.82% | ||
| Dividend Yield (f) | 2.27% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.72 | ||
| Price to Tang. Book | 0.73 | ||
| Price to Free Cashflow | 52.28 | ||
| Price to Sales | 1.01 | ||
| EV to EBITDA | 4.08 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.53% | ||
| Return on Equity | 8.27% | ||
| Operating Margin | 11.11% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 215,949.55 | 221,039.96 | 262,522.02 | 278,943.3 | 288,706.73 | 300,000 | 317,000 | 5.46% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -14.49 | +6.97 | +58.08 | +9.52 | +2.26 | +9.58 | +4.39 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
KOREA UNITED PHARM. INC. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals. The Company’s products include remedies for gastrointestinal system, cardiovascular, hematopoietic system, respiratory system, central nervous system, musculoskeletal system, endocrine and metabolic system, allergy and immune system, as well as anti-infectives, gynecological agents, vitamins, nutrition products, anticancer medicines and others. It also provides active pharmaceutical ingredients (APIs) and various health food products. The Company distributes its products within domestic market and to overseas markets.
Directors
- Deok Yeong Kang CEO (66)
- Hyeong Rae Kim MDR (58)
- Won Tae Jung MDR (50)
- Gwi Ja Kim MDR (56)
- Jin Ho Cho MDR (59)
- Yong Wu Cho OTH (53)
- Oh Byeong Gwon OTH (45)
- Jang Yeon Cho NID (60)
- Bak Gwon NID (70)
- Yeon Taek Lee NID (56)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 3rd, 1987
- Public Since
- October 23rd, 2007
- No. of Shareholders
- 28,350
- No. of Employees
- 936
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 14,711,269
- Address
- 25-23, Nojanggongdan-gil, Jeondong-myeon, SEJONG, 30011
- Web
- https://www.kup.co.kr
- Phone
- +82 25163041
- Auditors
- Sunjin Accounting Corp.
Upcoming Events for 033270
Similar to 033270
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
What is the Korea United Pharm share price?
As of Today at 23:53 UTC, shares in Korea United Pharm are trading at KR₩19,800. This share price information is delayed by 15 minutes.
How has the Korea United Pharm share price performed this year?
Shares in Korea United Pharm last closed at KR₩19,800 and the price had moved by -13.16% over the past 365 days. In terms of relative price strength the Korea United Pharm share price has underperformed the FTSE Developed Asia Pacific Index by -12.17% over the past year.
What are the analyst and broker recommendations for Korea United Pharm?
The overall consensus recommendation for Korea United Pharm is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Korea United Pharm dividend yield?
The Korea United Pharm dividend yield is 2.27% based on the trailing twelve month period.
Does Korea United Pharm pay a dividend?
Last year, Korea United Pharm paid a total dividend of KR₩450, and it currently has a trailing dividend yield of 2.27%. We do not have any data on when Korea United Pharm is to next pay dividends.
When does Korea United Pharm next pay dividends?
We do not have data on when Korea United Pharm is to next pay dividends. The historic dividend yield on Korea United Pharm shares is currently 2.27%.
How do I buy Korea United Pharm shares?
To buy shares in Korea United Pharm you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Korea United Pharm?
As of the previous close price of KR₩19,800, shares in Korea United Pharm had a market capitalisation of KR₩289bn.
Where are Korea United Pharm shares listed?
Here are the trading details for Korea United Pharm:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 033270
What kind of share is Korea United Pharm?
Based on an overall assessment of its quality, value and momentum Korea United Pharm is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Korea United Pharm share price forecast for 2025?
The analyst consensus target price for shares in Korea United Pharm is KR₩28,199. That is 42.42% above the last closing price of KR₩19,800.
Analysts covering Korea United Pharm currently have a consensus Earnings Per Share (EPS) forecast of KR₩3,712 for the next financial year.
Find out moreWhat is the trend in the Korea United Pharm share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Korea United Pharm. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +1.36%.
As of the last closing price of KR₩19,800, shares in Korea United Pharm were trading -3.1% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Korea United Pharm PE Ratio?
The Korea United Pharm PE ratio based on its reported earnings over the past 12 months is 5.26. The shares last closed at KR₩19,800.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Korea United Pharm?
Korea United Pharm's management team is headed by:
- Deok Yeong Kang - CEO
- Hyeong Rae Kim - MDR
- Won Tae Jung - MDR
- Gwi Ja Kim - MDR
- Jin Ho Cho - MDR
- Yong Wu Cho - OTH
- Oh Byeong Gwon - OTH
- Jang Yeon Cho - NID
- Bak Gwon - NID
- Yeon Taek Lee - NID